Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BDTX-1535 |
| Trade Name | |
| Synonyms | BDTX1535|BDTX 1535 |
| Drug Descriptions |
BDTX-1535 is an irreversible fourth-generation EGFR inhibitor with activity against EGFR mutations, including mutations associated with resistance to third-generation inhibitors, which potentially reduces tumor growth (Eur J Cancer Vol 174, Supp 1:S14; Eur J Cancer, Vol 174, Supp 1:S22). |
| DrugClasses | EGFR Inhibitor 4th gen 19 |
| CAS Registry Number | NA |
| NCIT ID | C187115 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BDTX-1535 | BDTX-1535 | 0 | 2 |
| BDTX-1535 + Temozolomide | BDTX-1535 Temozolomide | 0 | 2 |